# Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

> **NCT03041012** · PHASE2 · COMPLETED · sponsor: **Aarhus University Hospital** · enrollment: 60 (actual)

## Conditions studied

- Hiv

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** 3BNC117
- **DRUG:** Antiretrovirals

## Key facts

- **NCT ID:** NCT03041012
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-20
- **Primary completion:** 2021-08-20
- **Final completion:** 2022-12-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041012, "Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03041012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*